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ABSTRACT
Background: The effect of crenotherapy on major mucosal markers of inflammation, TNF alpha, human beta-defensins 2 (hBD-2), and calprotectin, are
largely unexplored in pediatric chronic rhinosinusitis (CRS). The aim of this study was to investigate the effects of crenotherapy with sulfate-sodium-chloride
water on mucosal markers of inflammation in children with CRS.
Methods: Children with CRS received 15-day crenotherapy consisting of sulfate-sodium-chloride thermal water inhalations by nasal aerosol (15
minutes/day). Concentrations of nasal mucosal markers of inflammation (TNF alpha, hBD-2, and calprotectin) were measured before and after crenotherapy.
Presence of specific symptoms (nasal obstruction, nasal discharge, facial pain, sense of smell, and cough), value of symptoms score sino-nasal 5 (SN5), quality
of life (QoL) score (1 [worse] to 10 [optimal]) were also assessed.
Results: After crenotherapy a significant reduction was observed in TNF alpha (from 0.14  0.02 to 0.08  0.01; p  0.001), calprotectin (from 2.9 
1.0 to 1.9  0.5; p  9.001), and hBD-2 (from 2.0  0.1 to 0.9  0.6; p  0.001) concentrations. A significant (p  0.05) reduction in number of subjects
presenting symptoms of nasal obstruction (100% versus 40%), nasal discharge (33% versus 13%), facial pain (30% versus 10%), and sense of smell (60%
versus 20%) was observed. A significant improvement of SN5 (from 3.07  0.76 to 2.08  0.42; p  0.001) was observed after the crenotherapy. QoL also
improved after crenotherapy (from 4.2  1.1 to 6.6  1.0; p  0.001).
Conclusion: Crenotherapy induced a down-regulation of nasal mucosal inflammatory mediators in children with CRS.
(Am J Rhinol Allergy 26, e15–e19, 2012; doi: 10.2500/ajra.2012.26.3733)
Chronic rhinosinusitis (CRS) is one of the most common diseasesin western countries. Although the exact pathogenesis of CRS
remains unclear, the underlying mechanisms involve different in-
flammatory mediators, such as proinflammatory cytokines (TNF-)
and several antimicrobial and immunoregulatory peptides, including
calprotectin and human -defensins 2 (hBD-2).1,2 Although the eosin-
ophilic inflammation is typical of adult patients with CRS, the inflam-
matory response in children is characterized by a mixed lymphocyte
population, macrophages and neutrophils, suggesting differences in
the pathogenic mechanism.3 Neutrophils play a fundamental role in
the inflammatory process; they release inflammatory cytokines, such
as TNF-, and antimicrobial peptide, including defensins and calpro-
tectin.4–6 Calprotectin is among the most abundant cytoplasmic pro-
teins in neutrophils and macrophages, and it is found in all body
fluids in proportion to the degree of inflammation.7 Elevated serum
levels of calprotectin have been reported in several inflammatory
conditions, including cystic fibrosis, rheumatoid arthritis, and sys-
temic infections.8–11 Human -defensin 2 is an inducible antimicrobial
peptide widely expressed by epithelial cells and involved most obvi-
ously in mucosal response in inflammatory and/or infectious condi-
tions.12,13 Human -defensin 2 exerts chemotactic properties on den-
dritic cells and human neutrophils.14,15 Elevated levels of hBD-2 have
been founded in many human diseases characterized by chronic
inflammation.16–19
Crenotherapy (from the Greek , spring fountain), is a com-
plex of practices using water, with different mineral components and
different physical properties, to cure many pathologies, mainly dis-
eases of the respiratory, digestive and urinary tract, of the skin, and
rheumatic diseases.20 Crenotherapy has been approved as a drug in
many countries, with specific therapeutic indications, targeted doses,
and contraindications, but the exact mechanisms of action are still
under active research. Clinical findings suggest an anti-inflammatory
effect of crenotherapy in adult respiratory system diseases,21–26 but
data in the pediatric population are still very limited. The aim of this
study was to investigate the effects of crenotherapy with sulfate-
sodium-chloride water on mucosal markers of inflammation in chil-
dren with CRS.
METHODS
Study Design
The present investigation was a prospective study on pediatric
patients with CRS. The study protocol was approved by the Ethics
Committee of the University of Naples “Federico II.” Written in-
formed consent was obtained from all care givers of subjects before
the procedures were performed.
Population
The trial was performed in collaboration with family pediatricians,
who were in the Italian public health care system, for children up to
16 years of age. The family pediatricians were invited to contact the
study coordinator at the Department of Pediatrics if a case of CRS was
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suspected. Subjects considered eligible for the study were (1) aged
2–12 years; (2) had one or more of the following sinonasal symptoms:
nasal discharge, nasal congestion, nasal obstruction, postnasal drip,
daytime cough, or foul breath (fetor oris); (3) had active symptoms at
the time of initial evaluation; (4) failed courses of antibiotics, saline
irrigation, nasal steroids, or antihistamine; (5) and had persistent
symptoms for 1 month. Eligible patients were evaluated by two
otolaryngologists with great experience in the pediatric field that
confirmed the diagnosis of CRS and invited the children and their
families to participate in the study. The diagnosis of certainty of CRS
was based on direct observation by nasal fibroendoscopy of nasal
turbinates, middle meatus, and rhinopharynx, detecting mucopuru-
lent discharge from the middle meatus and/or edema or mucosal
obstruction.27 All eligible subjects had full clinical evaluation and
allergy and immunodeficiency workup. Staging of CRS was per-
formed according to previous validated clinical score, viz., sino-nasal
5 (SN5).28 Children with indication of surgery (primary diagnosis of
obstructive sleep apnea syndrome caused by tonsillar hyperplasia),
chronic diseases, immunodeficiency, neurological impairment, topi-
cal or systemic therapies with drugs that interfere with the character-
istics of nasal inflammation (steroids, nonsteroidal anti-inflammatory
drugs, antihistamines, and vasoconstrictors) in the previous 4 weeks,
varicose veins of the nasal septum, suspect of ciliary abnormalities,
previous sinonasal surgery, malformations of the upper airway, si-
nonasal osteoneogenesis, sinonasal tumors or obstructive lesions, a
history of facial trauma that distorted the sinus anatomy, or suspect of
ciliary dysfunction requiring biopsy, and/or inability to perform a
complete course of crenotherapy were excluded. Seventy-six consec-
utive patients with diagnosis of CRS were eligible and were enrolled
in the study. Sixty subjects completed the study protocol. The results
were compared with those obtained in a population of healthy chil-
dren consecutively observed at our center because routine examina-
tion before vaccination program. The demographic characteristics of
healthy children were comparable with children affected by CRS.
These subjects were evaluated by otolaryngologists with experience
in the pediatric field to exclude the presence of inflammation in the
upper airway. Sixty-two children were observed, 12 were excluded
because of mild upper respiratory infections, and 50 subjects were
enrolled (28 boys; mean age, 3.4  1.0 years).
Intervention and Data Collection
Enrolled patients with CRS received a 15-day course of sulfate-
sodium-chloride thermal water inhalations by nasal aerosol (15 min-
utes/day). Therapy was performed in a thermal site in the island of
Ischia approved by the Italian National Health System. The compo-
sition of the thermal water is reported in the Table 1. Demographic
and clinical variables of all study subjects were collected in a specific
chart. The severity of the symptoms and quality of life (QoL) were
measured by SN5 and QoL score according to previous criteria28 in
each patient at the time of enrollment (T0), at the end of a 15-day
course of crenotherapy (T1), and 4 weeks later (T2). SN5 and QoL
scores were completed by patients in collaboration with caregivers
unaware of the study aims. Before and immediately after creno-
therapy a nasal mucous sample was collected by sterile cannula (8
French) through lavage of the nasal cavity using 5 mL of physiolog-
ical saline, as previously reported.29 Mucus samples were placed in
15-mL tubes containing 2 mL of buffer and then stored at20°C. Data
collection and nasal mucus samples, with an identification code, were
sent to the Coordinator Center. A good compliance to crenotherapy
was defined if the subject underwent at least of 90% of prescribed
therapy.
Laboratory Measurements
Nasal mucus samples were thawed slowly at room temperature,
diluted with distilled water, subjected to mild mechanical agitation
for 60 minutes, and centrifuged at 3000 rpm for 20 minutes, and the
supernatant was collected and frozen at 20°C for subsequent deter-
minations. Quantitative determinations of TNF-, calprotectin, and
hBD-2 were performed using commercial ELISA kits (TNF alpha
single analyte ELISA Kit; Orgenium, Vantaa, Finland; Calprest Euro-
spital Trieste, Italy; Human beta defensin 2 ELISA Kit Protocol; Phoe-
nix Pharmaceuticals, Inc., Burlingame CA). In brief, for calprotectin
determinations, 100 	L of each sample was added to the wells of a
plate and incubated at room temperature for 45 minutes. The plate
was then washed three times with diluted washing solution, and 100
	L of purified rabbit anti-calprotectin antibodies conjugated with
alkaline phosphatase were added and incubated for 45 minutes at
room temperature. A second washing procedure was performed; 100
	L of enzyme substrate solution was added to each well, and optical
density was read at 405 nm. Nasal mucous calprotectin was calcu-
lated from the standards and expressed as micrograms per milliliter.
For hBD-2 determinations,100 	L of each sample was added to the
wells of a plate and incubated at room temperature for 120 minutes.
The plate was then washed four times with diluted washing solution,
and 100 	L of biotinylated anti--defensin 2 detection antibody was
added and incubated for 120 minutes at room temperature. A second
washing procedure was performed; 100 	L of streptavidin horserad-
ish peroxidase solution was added to each well and incubated for 30
minutes at room temperature, and after addition of 100 	L of stop
solution, optical density was read at 450 nm. Nasal mucous hBD-2
was calculated from the standards and expressed as nanograms per
milliliter. For TNF- determinations, 50 	L of each sample was added
to the wells of a plate and incubated at room temperature for 60
minutes. The plate was then washed five times with diluted washing
solution, and 50 	L of biotin antibody was added and incubated for
30 minutes at room temperature. A second washing procedure was
performed; 50 	L of streptavidin horseradish peroxidase solution was
added to each well and incubated for 30 minutes at room tempera-
ture. A third washing was performed. After addition of 50 	L of
tetramethylbenzidine substrate solution, incubation for 20 minutes
was performed. Optical density was read at 450 nm. Nasal mucous
TNF-was calculated from the standards and expressed as picograms
per milliliter. Determinations were performed in triplicate and re-
peated on the samples collected before and after the cycle of creno-
therapy.
Table 1 Essential chemical composition of the sulphate-sodium-
chloride water investigated in the study
Parameter Results
Temperature at source 45°C
Acidity (pH) 7.12
Conductivity (at source; at 20°C) 8.30 	S/cm
Ammonium 0.62 mg/dL
Nitrites 0.06 mg/dL
Nitrate 41.00 mg/dL
Sodium 1700.00 mg/dL
Potassium 105.00 mg/dL
Calcium 100.20 mg/dL
Magnesium 82.15 mg/dL
Iron 0.01 mg/dL
Manganese 0.20 mg/dL
Lithium 0.50 mg/dL
Barium 1.00 mg/dL
Chloride 2800.79 mg/dL
Sulphate 473.20 mg/dL
Hydrogen carbonate 658.80 mg/dL
Silica 70.04 mg/dL
Note: The analysis was provided by Department of Pharmaceutical Chem-
istry and Toxicology, University of Naples Federico II, test report 41/2008,
February 28, 2008.
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Statistics
Statistical analysis was performed by a statistician blind to study
aims. For categorical variables the Pearson chi-square test was per-
formed, unless the exact method was required for frequency tables
when 20% of the expected values were 5. Because of the Gaussian
distribution of continuous variables assessed by Kolmogorov-Smir-
nov analysis, continuous variables were expressed as mean and 95%
CI and analyzed by the one-way ANOVA procedure with the Bon-
ferroni test for the post hoc analysis. A multivariate analysis was used
to exclude the influence of demographic data on clinical and labora-
tory effects of crenotherapy. Spearman rank test was used to define
coefficient of correlation (r) between SN5 score and levels of TNF-,
hBD-2, and calprotectin. Linear regression analysis was used to study
the possible influence of such variables on the levels of TNF-, hBD-2,
and calprotectin. All tests of significance were two sided. A value of
p 
 0.05 was considered significant. Statistical analysis was per-
formed with SPSS Version 16.0 for Windows (SPSS, Inc., Chicago, IL).
RESULTS
From January 2008 to April 2009, 76 consecutive patients with a
positive diagnosis of CRS were evaluated. Thirteen patients were
excluded because of topical or systemic therapy with drugs that
interfere with the characteristics of nasal inflammation (steroids, non-
steroidal anti-inflammatory drugs, antihistamines, and vasoconstric-
tors) in the previous 4 weeks,7 immunodeficiency,2 diabetes,2 malfor-
mations of the upper airways,1 and varicose veins of the nasal
septum.1 Three patients were lost to follow-up. Sixty subjects (28
boys; mean age, 3.3 0.9 years) completed the study protocol. Creno-
therapy was well accepted by all study subjects, as suggested by the
good compliance observed in all enrolled children. The TNF-, cal-
protectin, and hBD-2 levels at baseline were significantly higher in
children with CRS compared with healthy subjects. After a 15-day
course of crenotherapy a significant reduction toward normal values
was observed as shown in the Fig. 1. At the end of treatment with
sulfate-sodium-chloride water a positive clinical response was ob-
served in all patients with a significant reduction of the occurrence of
nasal obstruction, nasal discharge, facial pain, and sense of smell
(Table 2). A significant improvement in the SN5 score was observed
after crenotherapy (Table 3) and at follow-up visit performed after 4
weeks. QoL also improved after crenotherapy (from 4.2 1.1 to 6.6
1.0; p  0.001) and remained stable after 4 weeks (6.6  1.0).
DISCUSSION
Although more basic and clinical data are still needed, creno-
therapy is considered useful in the therapeutic approach for adult
patients with CRS, reducing the use of other therapies and medical
costs.21–26 Crenotherapy is generally well accepted and tolerated by
patients and in literature no cases of toxicity or neoplasm occurrence
due to thermal water inhalation have been documented in the hun-
dreds of thousands of patients treated.20–26 The results of our study
showed that even in pediatric patients with CRS, crenotherapy sig-
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Figure 1. Results of the determination of
(A) TNF-, (B) human -defensin 2
(hBD-2), and (C) calprotectin in nasal se-
cretions of children with chronic rhinosi-
nusitis (CRS) before (T0) and after a 15-
day course (T1) of crenotherapy. For
comparison, results obtained in healthy
children (controls) were also provided in
the figure. * p  0.05 T1 versus T0; #p 
0.05 T0 versus controls.
Table 2 Clinical manifestations before (T0) and after (T1)
crenotherapy in children with CRS
Symptoms, n (%) T0 T1 p value
Nasal obstruction 60 (100) 24 (40) 0.001
Nasal discharge 20 (33) 8 (13) 0.010
Facial pain 18 (30) 6 (10) 0.006
Sense of smell 36 (60) 12 (20) 0.001
Cough 11 (18) 5 (8.3) 0.107
CRS  chronic rhinosinusitis.
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nificantly improve nasal obstruction, nasal discharge, facial pain, and
reduction of smell, all typical symptoms of CRS. Our goal was to
evaluate the mechanisms behind the clinical effects of crenotherapy in
pediatric patients with CRS. We observed that the positive effect
exerted by crenotherapy on the persistent symptomatic inflammation
of the nasal mucosa involves a modulation of proinflammatory cyto-
kines and immunoregulatory peptides; in fact, in our study we ob-
served a significant reduction toward normal values of TNF-, cal-
protectin, and hBD-2 after a 15-day course of crenotherapy. The
positive modulation of TNF- is important because during inflam-
mation this cytokine mediates the induction of peptides, such as
hBD-213 and other proinflammatory cytokines involved in the alter-
ations of the nasal mucosa, which usually occur in patients with CRS.
In this light, crenotherapy can be regarded as an old therapy, which
is now being reassessed and revived scientifically. In particular, our
study is one of the first studies to investigate the efficacy of such
therapy in the treatment of respiratory disorders of childhood and to
assess the role of innate immunity in the mechanism of action of
crenotherapy in childhood.
In a recent study Tieu et al.30 examined the expression of calpro-
tectin using ELISA in nasal lavage samples from 40 adult control
subjects, patients with CRS with nasal polyps (CRSwNPs), and CRS
without nasal polyps (CRSsNPs). Calprotectin levels were signifi-
cantly decreased in nasal lavage samples of patients with CRSwNPs
when compared with those seen in control subjects (p  0.05). The
authors suggest that reduced levels should be considered as a possi-
ble contributing factor in CRS pathogenesis. In another recent study,
32 adult patients with CRSwNPs and 10 control subjects were en-
rolled. In this study, the authors showed that epithelial cells derived
from patients with recalcitrant CRSwNPs displayed decreased ex-
pression of hBD-2.31 In our pediatric population, we found, appar-
ently in contrast with those reported in adults, higher values of
calprotectin and hBD-2 in patients with CRS compared with controls,
whereas after crenotherapy these values tended to return to a normal
level found in healthy subjects. However, one should consider that
CRS is a heterogeneous group of inflammatory diseases of the nasal
and paranasal cavities either accompanied by polyp formation or
without polyps. The tissue inflammatory response in patients with
CRSsNPs has been shown to be highly neutrophilic with a tendency
toward TH1 polarization, whereas CRSwNP inflammatory responses
are characterized by eosinophilia with a TH2 skewing.32 Although the
eosinophilic inflammation is typical of adult patients with CRS, the
inflammatory response in children is characterized by a mixed lym-
phocyte population, macrophages, and neutrophils, suggesting dif-
ferences in the pathogenic mechanism.3 A diverse spectrum of alter-
ations involving histopathology, inflammatory cell and T-cell
patterns, remodeling parameters, IgE production, microorganisms,
and epithelial barrier malfunctions is reported in the search to de-
scribe the pathogenesis of this heterogeneous group of upper airway
diseases.33,34 Distinct features of CRSwNPs and CRSsNPs are in line
with the results obtained in our study group. The studies conducted
in adult patients reported diminished levels of calprotectin and hBD-2
expression in patients with CRSwNP while we have enrolled children
without nasal polyps, a form with distinct histopathological features
and, consequently, with different expression of mucosal markers of
inflammation.
CONCLUSION
The present study shows that crenotherapy with sulfate-sodium-
chloride water modulates the expression of proinflammatory cyto-
kines and immunoregulatory and antimicrobial peptides in nasal
secretions of pediatric patients with CRS after a 15-day course of
thermal water inhalations by nasal aerosol. At the end of the creno-
therapy treatment a significant improvement of the persistent symp-
tomatic inflammation of the nasal mucosa was observed. It is proba-
bly because of a positive effect exerted by the thermal water on the
alterations of the epithelial immune barrier function, which usually
occurs in patients with CRS. These evidences suggest that creno-
therapy could be considered as an efficacious therapeutic tool in the
management of these patients. In particular, the modulatory effect on
TNF-, calprotectin, and hBD-2 levels could be helpful for a better
knowledge of the mechanisms of action of crenotherapy, which could
open the way for new possible applications of this therapeutic strat-
egy in other conditions characterized by inflammation. The therapeu-
tic effects of the thermal water are probably because of its mechanical
cleaning function and its physical and chemical composition, but
other studies are needed to define the components of the thermal
waters involved in these beneficial effects.
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